Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study.

PloS One
Shawn D AaronFelix Ratjen

Abstract

Many patients with cystic fibrosis develop persistent airway infection/colonization with Aspergillus fumigatus, however the impact of A. fumigatus on clinical outcomes remains unclear. The objective of this study was to determine whether treatment directed against Aspergillus fumigatus improves pulmonary function and clinical outcomes in patients with cystic fibrosis (CF). We performed a double-blind randomized placebo-controlled pilot clinical trial involving 35 patients with CF whose sputum cultures were chronically positive for A. fumigatus. Participants were centrally randomized to receive either oral itraconazole 5 mg/kg/d (N = 18) or placebo (N = 17) for 24 weeks. The primary outcome was the proportion of patients who experienced a respiratory exacerbation requiring intravenous antibiotics over the 24 week treatment period. Secondary outcomes included changes in FEV(1) and quality of life. Over the 24 week treatment period, 4 of 18 (22%) patients randomized to itraconazole experienced a respiratory exacerbation requiring intravenous antibiotics, compared to 5 of 16 (31%) placebo treated patients, P = 0.70. FEV(1) declined by 4.62% over 24 weeks in the patients randomized to itraconazole, compared to a 0.32% improvement in...Continue Reading

References

Dec 1, 1994·American Journal of Respiratory and Critical Care Medicine·J M el-DahrP W Heymann
Feb 1, 1994·Archives of Disease in Childhood·E J SimmondsE G Evans
Feb 24, 2001·Allergy and Asthma Proceedings·M Jain
Sep 20, 2001·Thorax·M Corey
Nov 1, 2001·The Cochrane Database of Systematic Reviews·P WarkP G Gibson
Sep 17, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David A StevensUNKNOWN Participants in the Cystic Fibrosis Foundation Consensus Conference
Mar 27, 2004·The Journal of Antimicrobial Chemotherapy·Steven P ConwayHelen Cunliffe
Oct 26, 2005·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Tom HilliardJane Davies
Jul 15, 2006·Chest·David ShoseyovEitan Kerem
Aug 20, 2010·Current Opinion in Pulmonary Medicine·Richard B Moss

❮ Previous
Next ❯

Citations

Sep 18, 2014·Current Opinion in Pulmonary Medicine·Imogen C Felton, Nicholas J Simmonds
Aug 30, 2014·Annals of the American Thoracic Society·James F ChmielFelix A Ratjen
Sep 26, 2013·Current Opinion in Pulmonary Medicine·Peter G MiddletonWieland Meyer
Sep 12, 2012·Current Opinion in Pulmonary Medicine·Jennifer J SpeirsJeffrey M Beekman
May 30, 2014·Expert Review of Respiratory Medicine·Andrew M JonesDavid W Denning
Mar 23, 2013·Paediatric Respiratory Reviews·Georgina K RussellNicholas J Simmonds
May 19, 2017·Mycopathologia·Sanjay H Chotirmall, Maria Teresa Martin-Gomez
Nov 22, 2016·Pediatric Pulmonology·Abigail C CowleyAlexander Horsley
Jul 12, 2018·Pediatric Pulmonology·Michael C Tracy, Richard B Moss
Mar 1, 2019·Medical Mycology·Adilia WarrisDarius Armstrong-James
Aug 5, 2017·Mycopathologia·A SinghA Hector
Nov 8, 2016·The Cochrane Database of Systematic Reviews·Heather E Elphick, Kevin W Southern
Aug 21, 2012·American Journal of Respiratory and Critical Care Medicine·Catherine A CoughlanNoel G McElvaney
Mar 19, 2013·American Journal of Respiratory and Critical Care Medicine·Keven M Robinson, John F Alcorn
Jan 12, 2013·American Journal of Respiratory and Critical Care Medicine·Rossana G IannittiLuigina Romani
Jul 27, 2017·Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia·Rodrigo Abensur AthanazioUNKNOWN Grupo de Trabalho das Diretrizes Brasileiras de Diagnóstico e Tratamento da Fibrose Cística.
Jun 18, 2019·Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine·Emanuele DelfinoDaniele Roberto Giacobbe
Nov 21, 2019·American Journal of Respiratory and Critical Care Medicine·Oded BreuerDaan Caudri
May 3, 2013·American Journal of Respiratory and Critical Care Medicine·Christopher H Goss, Felix Ratjen
Feb 25, 2019·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Gina Hong, Noah Lechtzin
Mar 7, 2021·Microorganisms·Anatte MargalitKevin Kavanagh
Apr 2, 2021·Infection and Drug Resistance·Lauren C MageeNauman Chaudary
Apr 4, 2021·Antibiotics·Aidan K Curran, David L Hava
Jun 4, 2013·The Journal of Allergy and Clinical Immunology·Caroline G BaxterDavid W Denning
Jun 3, 2021·Pathogens·T Spencer PooreEdith T Zemanick
Aug 2, 2021·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Gina HongCarsten Schwarz

❮ Previous
Next ❯

Methods Mentioned

BETA
nucleic acid amplification

Software Mentioned

SAS

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Jane C LiuErol A Gaillard
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Hanneke A de ValkJacques F G M Meis
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
S BentleyIan Balfour-Lynn
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
A M M de VrankrijkerT F W Wolfs
© 2021 Meta ULC. All rights reserved